PDF(Pubmed)
Abstract：
A challenging task in routine practice is finding the distinction between benign and malignant paragangliomas and pheochromocytomas. The aim of this study is to conduct a comparative analysis of angiogenesis by assessing intratumoral microvascular density (MVD) with immunohistochemical (IHC) markers (CD31, CD34, CD105, ERG), and S100 immunoreactivity, Ki67 proliferative index, succinate dehydrogenase B (SDHB) expressiveness, tumor size with one the most utilized score Pheochromocytoma of Adrenal Gland Scales Score (PASS), using tissue microarray (TMA) with 115 tumor samples, 61 benign (PASS < 4) and 54 potentially malignant (PASS ≥ 4). We found no notable difference between intratumoral MVD and potentially malignant behavior. The group of potentially malignant tumors is significantly larger in size, has lower intratumoral MVD, and a decreased number of S100 labeled sustentacular cells. Both groups have low proliferative activity (mean Ki67 is 1.02 and 1.22, respectively). Most tumors maintain SDHB expression, only 6 cases (5.2%) showed a loss of expression (4 of them in PASS < 4 group and 2 in PASS ≥ 4). PASS score is easily available for assessment and complemented with markers of biological behavior to complete the risk stratification algorithm. Size is directly related to PASS score and malignancy. Intratumoral MVD is extensively developed but it is not crucial in evaluating the malignant potential.
摘要：
常规实践中的一项艰巨任务是找到良性和恶性副神经节瘤与嗜铬细胞瘤之间的区别。这项研究的目的是通过评估肿瘤内微血管密度（MVD）与免疫组织化学（IHC）标记（CD31，CD34，CD105，ERG）进行血管生成的比较分析，和S100免疫反应性，Ki67增殖指数,琥珀酸脱氢酶B（SDHB）的表达，肿瘤大小与肾上腺腺体量表评分（PASS）的嗜铬细胞瘤，使用115个肿瘤样本的组织微阵列（TMA），61例良性（PASS<4），54例潜在恶性（PASS≥4）。我们发现肿瘤内MVD和潜在的恶性行为之间没有显着差异。潜在的恶性肿瘤组的体积明显更大，肿瘤内MVD较低，S100标记的软骨细胞数量减少。两组均具有低增殖活性(平均Ki67分别为1.02和1.22)。大多数肿瘤维持SDHB表达，只有6例(5.2%)表达缺失(PASS<4组4例,PASS≥4组2例)。PASS评分易于评估，并辅以生物学行为标记，以完成风险分层算法。大小与PASS评分和恶性肿瘤直接相关。肿瘤内MVD已广泛发展，但在评估恶性潜能方面并不重要。
